APO Research
Talk to an analyst

APO RESEARCH · REPORT

Imatinib Mesylate Drugs

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Imatinib Mesylate Drugs Market Outlook and Growth Opportunities 2026

22 December 2025190 pages

Choose your research edition.

Industry ResearchImatinib Mesylate Drugs Industry Research Report 2026110 pages · $2,950 USDIndustry Growth & TrendsGlobal Imatinib Mesylate Drugs Industry Growth and Trends Forecast to 203273 pages · $3,450 USDMarket StructureGlobal Imatinib Mesylate Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032176 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Imatinib Mesylate Drugs Market Outlook and Growth Opportunities 2026190 pages · $4,250 USDMarket Analysis & ForecastGlobal Imatinib Mesylate Drugs Market Analysis and Forecast 2026-2032192 pages · $4,950 USD

Market perspective

The global Imatinib Mesylate Drugs market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Imatinib Mesylate Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Imatinib Mesylate Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Imatinib Mesylate Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Imatinib Mesylate Drugs market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Imatinib Mesylate Drugs market include Novartis. among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Imatinib Mesylate Drugs market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Imatinib Mesylate Drugs and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Imatinib Mesylate Drugs sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Imatinib Mesylate Drugs market size, projected growth trends, production technologies, key applications, and end-use industries.

Imatinib Mesylate Drugs Segment by Company

Novartis

Imatinib Mesylate Drugs Segment by Type

100mg

400mg

Imatinib Mesylate Drugs Segment by Application

Hospital

Pharmacy

Imatinib Mesylate Drugs Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Imatinib Mesylate Drugs status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Imatinib Mesylate Drugs market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Imatinib Mesylate Drugs significant trends, drivers, influence factors in global and regions.

6. To analyze Imatinib Mesylate Drugs competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Imatinib Mesylate Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Imatinib Mesylate Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Imatinib Mesylate Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Imatinib Mesylate Drugs market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Imatinib Mesylate Drugs industry.

Chapter 3: Detailed analysis of Imatinib Mesylate Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Imatinib Mesylate Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Imatinib Mesylate Drugs in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Imatinib Mesylate Drugs Industry Trends Table 2. Imatinib Mesylate Drugs Industry Drivers Table 3. Imatinib Mesylate Drugs Industry Opportunities and Challenges Table 4. Imatinib Mesylate Drugs Industry Restraints Table 5. Global Imatinib Mesylate Drugs Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Imatinib Mesylate Drugs Revenue Share by Company (2021-2026) Table 7. Global Imatinib Mesylate Drugs Sales Volume by Company (k units) & (2021-2026) Table 8. Global Imatinib Mesylate Drugs Sales Volume Share by Company (2021-2026) Table 9. Global Imatinib Mesylate Drugs Average Price (US$/unit) of Company (2021-2026) Table 10. Global Imatinib Mesylate Drugs Company Ranking, (2024-2026) & (USD Million) Table 11. Global Imatinib Mesylate Drugs Key Company Manufacturing Base & Headquarters Table 12. Global Imatinib Mesylate Drugs Company, Product Type & Application Table 13. Global Imatinib Mesylate Drugs Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Imatinib Mesylate Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of 100mg Table 18. Significant Companies of 400mg Table 19. Global Imatinib Mesylate Drugs Sales Volume by Type 2021 VS 2025 VS 2032 (k units) Table 20. Global Imatinib Mesylate Drugs Sales Volume by Type (2021-2026) & (k units) Table 21. Global Imatinib Mesylate Drugs Sales Volume by Type (2027-2032) & (k units) Table 22. Global Imatinib Mesylate Drugs Sales Volume Share by Type (2021-2026) Table 23. Global Imatinib Mesylate Drugs Sales Volume Share by Type (2027-2032) Table 24. Global Imatinib Mesylate Drugs Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global Imatinib Mesylate Drugs Sales Value by Type (2021-2026) & (US$ Million) Table 26. Global Imatinib Mesylate Drugs Sales Value by Type (2027-2032) & (US$ Million) Table 27. Global Imatinib Mesylate Drugs Sales Value Share by Type (2021-2026) Table 28. Global Imatinib Mesylate Drugs Sales Value Share by Type (2027-2032) Table 29. Significant Companies of Hospital Table 30. Significant Companies of Pharmacy Table 31. Global Imatinib Mesylate Drugs Sales Volume by Application 2021 VS 2025 VS 2032 (k units) Table 32. Global Imatinib Mesylate Drugs Sales Volume by Application (2021-2026) & (k units) Table 33. Global Imatinib Mesylate Drugs Sales Volume by Application (2027-2032) & (k units) Table 34. Global Imatinib Mesylate Drugs Sales Volume Share by Application (2021-2026) Table 35. Global Imatinib Mesylate Drugs Sales Volume Share by Application (2027-2032) Table 36. Global Imatinib Mesylate Drugs Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 37. Global Imatinib Mesylate Drugs Sales Value by Application (2021-2026) & (US$ Million) Table 38. Global Imatinib Mesylate Drugs Sales Value by Application (2027-2032) & (US$ Million) Table 39. Global Imatinib Mesylate Drugs Sales Value Share by Application (2021-2026) Table 40. Global Imatinib Mesylate Drugs Sales Value Share by Application (2027-2032) Table 41. Global Imatinib Mesylate Drugs Sales by Region: 2021 VS 2025 VS 2032 (k units) Table 42. Global Imatinib Mesylate Drugs Sales by Region (2021-2026) & (k units) Table 43. Global Imatinib Mesylate Drugs Sales Market Share by Region (2021-2026) Table 44. Global Imatinib Mesylate Drugs Sales by Region (2027-2032) & (k units) Table 45. Global Imatinib Mesylate Drugs Sales Market Share by Region (2027-2032) Table 46. Global Imatinib Mesylate Drugs Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 47. Global Imatinib Mesylate Drugs Sales Value by Region (2021-2026) & (US$ Million) Table 48. Global Imatinib Mesylate Drugs Sales Value Share by Region (2021-2026) Table 49. Global Imatinib Mesylate Drugs Sales Value by Region (2027-2032) & (US$ Million) Table 50. Global Imatinib Mesylate Drugs Sales Value Share by Region (2027-2032) Table 51. Global Imatinib Mesylate Drugs Market Average Price (US$/unit) by Region (2021-2026) Table 52. Global Imatinib Mesylate Drugs Market Average Price (US$/unit) by Region (2027-2032) Table 53. Global Imatinib Mesylate Drugs Sales by Country: 2021 VS 2025 VS 2032 (k units) Table 54. Global Imatinib Mesylate Drugs Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 55. Global Imatinib Mesylate Drugs Sales by Country (2021-2026) & (k units) Table 56. Global Imatinib Mesylate Drugs Sales Market Share by Country (2021-2026) Table 57. Global Imatinib Mesylate Drugs Sales by Country (2027-2032) & (k units) Table 58. Global Imatinib Mesylate Drugs Sales Market Share by Country (2027-2032) Table 59. Global Imatinib Mesylate Drugs Sales Value by Country (2021-2026) & (US$ Million) Table 60. Global Imatinib Mesylate Drugs Sales Value Market Share by Country (2021-2026) Table 61. Global Imatinib Mesylate Drugs Sales Value by Country (2027-2032) & (US$ Million) Table 62. Global Imatinib Mesylate Drugs Sales Value Market Share by Country (2027-2032) Table 63. Novartis Company Information Table 64. Novartis Business Overview Table 65. Novartis Imatinib Mesylate Drugs Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 66. Novartis Imatinib Mesylate Drugs Product Portfolio Table 67. Novartis Recent Development Table 68. Key Raw Materials Table 69. Raw Materials Key Suppliers Table 70. Imatinib Mesylate Drugs Distributors List Table 71. Imatinib Mesylate Drugs Customers List Table 72. Research Programs/Design for This Report Table 73. Authors List of This Report Table 74. Secondary Sources Table 75. Primary Sources List of Figures Figure 1. Imatinib Mesylate Drugs Product Image Figure 2. Global Imatinib Mesylate Drugs Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Imatinib Mesylate Drugs Sales Value (2021-2032) & (US$ Million) Figure 4. Global Imatinib Mesylate Drugs Sales (2021-2032) & (k units) Figure 5. Global Imatinib Mesylate Drugs Sales Average Price (US$/unit) & (2021-2032) Figure 6. Global Imatinib Mesylate Drugs Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. 100mg Image Figure 10. 400mg Image Figure 11. Global Imatinib Mesylate Drugs Sales Volume by Type (2021 VS 2025 VS 2032) & (k units) Figure 12. Global Imatinib Mesylate Drugs Sales Volume Share 2021 VS 2025 VS 2032 Figure 13. Global Imatinib Mesylate Drugs Sales Volume Share by Type (2021-2032) Figure 14. Global Imatinib Mesylate Drugs Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 15. Global Imatinib Mesylate Drugs Sales Value Share 2021 VS 2025 VS 2032 Figure 16. Global Imatinib Mesylate Drugs Sales Value Share by Type (2021-2032) Figure 17. Hospital Image Figure 18. Pharmacy Image Figure 19. Global Imatinib Mesylate Drugs Sales Volume by Application (2021 VS 2025 VS 2032) & (k units) Figure 20. Global Imatinib Mesylate Drugs Sales Volume Share 2021 VS 2025 VS 2032 Figure 21. Global Imatinib Mesylate Drugs Sales Volume Share by Application (2021-2032) Figure 22. Global Imatinib Mesylate Drugs Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 23. Global Imatinib Mesylate Drugs Sales Value Share 2021 VS 2025 VS 2032 Figure 24. Global Imatinib Mesylate Drugs Sales Value Share by Application (2021-2032) Figure 25. Global Imatinib Mesylate Drugs Sales by Region: 2021 VS 2025 VS 2032 (k units) Figure 26. Global Imatinib Mesylate Drugs Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 27. Global Imatinib Mesylate Drugs Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 28. Global Imatinib Mesylate Drugs Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 29. North America Imatinib Mesylate Drugs Sales Value (2021-2032) & (US$ Million) Figure 30. North America Imatinib Mesylate Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 31. Europe Imatinib Mesylate Drugs Sales Value (2021-2032) & (US$ Million) Figure 32. Europe Imatinib Mesylate Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 33. Asia-Pacific Imatinib Mesylate Drugs Sales Value (2021-2032) & (US$ Million) Figure 34. Asia-Pacific Imatinib Mesylate Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 35. South America Imatinib Mesylate Drugs Sales Value (2021-2032) & (US$ Million) Figure 36. South America Imatinib Mesylate Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 37. Middle East & Africa Imatinib Mesylate Drugs Sales Value (2021-2032) & (US$ Million) Figure 38. Middle East & Africa Imatinib Mesylate Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 39. USA Imatinib Mesylate Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 40. USA Imatinib Mesylate Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 41. USA Imatinib Mesylate Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 42. Canada Imatinib Mesylate Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. Canada Imatinib Mesylate Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. Canada Imatinib Mesylate Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. Mexico Imatinib Mesylate Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. Mexico Imatinib Mesylate Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. Mexico Imatinib Mesylate Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. Germany Imatinib Mesylate Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. Germany Imatinib Mesylate Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. Germany Imatinib Mesylate Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. France Imatinib Mesylate Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. France Imatinib Mesylate Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. France Imatinib Mesylate Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. U.K. Imatinib Mesylate Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. U.K. Imatinib Mesylate Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. U.K. Imatinib Mesylate Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. Italy Imatinib Mesylate Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. Italy Imatinib Mesylate Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. Italy Imatinib Mesylate Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Spain Imatinib Mesylate Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Spain Imatinib Mesylate Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Spain Imatinib Mesylate Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. Russia Imatinib Mesylate Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. Russia Imatinib Mesylate Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. Russia Imatinib Mesylate Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. Netherlands Imatinib Mesylate Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. Netherlands Imatinib Mesylate Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. Netherlands Imatinib Mesylate Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. Nordic Countries Imatinib Mesylate Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. Nordic Countries Imatinib Mesylate Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. Nordic Countries Imatinib Mesylate Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. China Imatinib Mesylate Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. China Imatinib Mesylate Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. China Imatinib Mesylate Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. Japan Imatinib Mesylate Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. Japan Imatinib Mesylate Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. Japan Imatinib Mesylate Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. South Korea Imatinib Mesylate Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. South Korea Imatinib Mesylate Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. South Korea Imatinib Mesylate Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. India Imatinib Mesylate Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. India Imatinib Mesylate Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. India Imatinib Mesylate Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. Australia Imatinib Mesylate Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. Australia Imatinib Mesylate Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. Australia Imatinib Mesylate Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Southeast Asia Imatinib Mesylate Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Southeast Asia Imatinib Mesylate Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Southeast Asia Imatinib Mesylate Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Brazil Imatinib Mesylate Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Brazil Imatinib Mesylate Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Brazil Imatinib Mesylate Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Argentina Imatinib Mesylate Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Argentina Imatinib Mesylate Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Argentina Imatinib Mesylate Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Chile Imatinib Mesylate Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Chile Imatinib Mesylate Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Chile Imatinib Mesylate Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Colombia Imatinib Mesylate Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Colombia Imatinib Mesylate Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Colombia Imatinib Mesylate Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. Peru Imatinib Mesylate Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. Peru Imatinib Mesylate Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. Peru Imatinib Mesylate Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. Saudi Arabia Imatinib Mesylate Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. Saudi Arabia Imatinib Mesylate Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. Saudi Arabia Imatinib Mesylate Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Israel Imatinib Mesylate Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Israel Arabia Imatinib Mesylate Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Israel Arabia Imatinib Mesylate Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. UAE Imatinib Mesylate Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. UAE Imatinib Mesylate Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. UAE Imatinib Mesylate Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. Turkey Imatinib Mesylate Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 115. Turkey Imatinib Mesylate Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 116. Turkey Imatinib Mesylate Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 117. Iran Imatinib Mesylate Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 118. Iran Imatinib Mesylate Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 119. Iran Imatinib Mesylate Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 120. Egypt Imatinib Mesylate Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 121. Egypt Imatinib Mesylate Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 122. Egypt Imatinib Mesylate Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 123. Imatinib Mesylate Drugs Value Chain Figure 124. Manufacturing Cost Structure Figure 125. Imatinib Mesylate Drugs Sales Mode & Process Figure 126. Direct Comparison with Distribution Share Figure 127. Distributors Profiles Figure 128. Years Considered Figure 129. Research Process Figure 130. Key Executives Interviewed

Scope & coverage.

Types
  • 100mg
  • 400mg
Applications
  • Hospital
  • Pharmacy
Companies covered
  • Novartis

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Imatinib Mesylate Drugs Sales Value (2021-2032)
  4. 1.2.2 Global Imatinib Mesylate Drugs Sales Volume (2021-2032)
  5. 1.2.3 Global Imatinib Mesylate Drugs Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Imatinib Mesylate Drugs Market Dynamics
  1. 2.1 Imatinib Mesylate Drugs Industry Trends
  2. 2.2 Imatinib Mesylate Drugs Industry Drivers
  3. 2.3 Imatinib Mesylate Drugs Industry Opportunities and Challenges
  4. 2.4 Imatinib Mesylate Drugs Industry Restraints
3 Imatinib Mesylate Drugs Market by Company
  1. 3.1 Global Imatinib Mesylate Drugs Company Revenue Ranking in 2025
  2. 3.2 Global Imatinib Mesylate Drugs Revenue by Company (2021-2026)
  3. 3.3 Global Imatinib Mesylate Drugs Sales Volume by Company (2021-2026)
  4. 3.4 Global Imatinib Mesylate Drugs Average Price by Company (2021-2026)
  5. 3.5 Global Imatinib Mesylate Drugs Company Ranking (2024-2026)
  6. 3.6 Global Imatinib Mesylate Drugs Company Manufacturing Base and Headquarters
  7. 3.7 Global Imatinib Mesylate Drugs Company Product Type and Application
  8. 3.8 Global Imatinib Mesylate Drugs Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Imatinib Mesylate Drugs Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Imatinib Mesylate Drugs Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Imatinib Mesylate Drugs Market by Type
  1. 4.1 Imatinib Mesylate Drugs Type Introduction
  2. 4.1.1 100mg
  3. 4.1.2 400mg
  4. 4.2 Global Imatinib Mesylate Drugs Sales Volume by Type
  5. 4.2.1 Global Imatinib Mesylate Drugs Sales Volume by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Imatinib Mesylate Drugs Sales Volume by Type (2021-2032)
  7. 4.2.3 Global Imatinib Mesylate Drugs Sales Volume Share by Type (2021-2032)
  8. 4.3 Global Imatinib Mesylate Drugs Sales Value by Type
  9. 4.3.1 Global Imatinib Mesylate Drugs Sales Value by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global Imatinib Mesylate Drugs Sales Value by Type (2021-2032)
  11. 4.3.3 Global Imatinib Mesylate Drugs Sales Value Share by Type (2021-2032)
5 Imatinib Mesylate Drugs Market by Application
  1. 5.1 Imatinib Mesylate Drugs Application Introduction
  2. 5.1.1 Hospital
  3. 5.1.2 Pharmacy
  4. 5.2 Global Imatinib Mesylate Drugs Sales Volume by Application
  5. 5.2.1 Global Imatinib Mesylate Drugs Sales Volume by Application (2021 VS 2025 VS 2032)
  6. 5.2.2 Global Imatinib Mesylate Drugs Sales Volume by Application (2021-2032)
  7. 5.2.3 Global Imatinib Mesylate Drugs Sales Volume Share by Application (2021-2032)
  8. 5.3 Global Imatinib Mesylate Drugs Sales Value by Application
  9. 5.3.1 Global Imatinib Mesylate Drugs Sales Value by Application (2021 VS 2025 VS 2032)
  10. 5.3.2 Global Imatinib Mesylate Drugs Sales Value by Application (2021-2032)
  11. 5.3.3 Global Imatinib Mesylate Drugs Sales Value Share by Application (2021-2032)
6 Imatinib Mesylate Drugs Regional Sales and Value Analysis
  1. 6.1 Global Imatinib Mesylate Drugs Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Imatinib Mesylate Drugs Sales by Region (2021-2032)
  3. 6.2.1 Global Imatinib Mesylate Drugs Sales by Region: 2021-2026
  4. 6.2.2 Global Imatinib Mesylate Drugs Sales by Region (2027-2032)
  5. 6.3 Global Imatinib Mesylate Drugs Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Imatinib Mesylate Drugs Sales Value by Region (2021-2032)
  7. 6.4.1 Global Imatinib Mesylate Drugs Sales Value by Region: 2021-2026
  8. 6.4.2 Global Imatinib Mesylate Drugs Sales Value by Region (2027-2032)
  9. 6.5 Global Imatinib Mesylate Drugs Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Imatinib Mesylate Drugs Sales Value (2021-2032)
  12. 6.6.2 North America Imatinib Mesylate Drugs Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Imatinib Mesylate Drugs Sales Value (2021-2032)
  15. 6.7.2 Europe Imatinib Mesylate Drugs Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Imatinib Mesylate Drugs Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Imatinib Mesylate Drugs Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Imatinib Mesylate Drugs Sales Value (2021-2032)
  21. 6.9.2 South America Imatinib Mesylate Drugs Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Imatinib Mesylate Drugs Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Imatinib Mesylate Drugs Sales Value Share by Country, 2025 VS 2032
7 Imatinib Mesylate Drugs Country-level Sales and Value Analysis
  1. 7.1 Global Imatinib Mesylate Drugs Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Imatinib Mesylate Drugs Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Imatinib Mesylate Drugs Sales by Country (2021-2032)
  4. 7.3.1 Global Imatinib Mesylate Drugs Sales by Country (2021-2026)
  5. 7.3.2 Global Imatinib Mesylate Drugs Sales by Country (2027-2032)
  6. 7.4 Global Imatinib Mesylate Drugs Sales Value by Country (2021-2032)
  7. 7.4.1 Global Imatinib Mesylate Drugs Sales Value by Country (2021-2026)
  8. 7.4.2 Global Imatinib Mesylate Drugs Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Imatinib Mesylate Drugs Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Imatinib Mesylate Drugs Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Imatinib Mesylate Drugs Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Imatinib Mesylate Drugs Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Imatinib Mesylate Drugs Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Imatinib Mesylate Drugs Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Imatinib Mesylate Drugs Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Imatinib Mesylate Drugs Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Imatinib Mesylate Drugs Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Imatinib Mesylate Drugs Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Imatinib Mesylate Drugs Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Imatinib Mesylate Drugs Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Imatinib Mesylate Drugs Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Imatinib Mesylate Drugs Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Imatinib Mesylate Drugs Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Imatinib Mesylate Drugs Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Imatinib Mesylate Drugs Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Imatinib Mesylate Drugs Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Imatinib Mesylate Drugs Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Imatinib Mesylate Drugs Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Imatinib Mesylate Drugs Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Imatinib Mesylate Drugs Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Imatinib Mesylate Drugs Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Imatinib Mesylate Drugs Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Imatinib Mesylate Drugs Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Imatinib Mesylate Drugs Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Imatinib Mesylate Drugs Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Imatinib Mesylate Drugs Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Imatinib Mesylate Drugs Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Imatinib Mesylate Drugs Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Imatinib Mesylate Drugs Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Imatinib Mesylate Drugs Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Imatinib Mesylate Drugs Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Imatinib Mesylate Drugs Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Imatinib Mesylate Drugs Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Imatinib Mesylate Drugs Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Imatinib Mesylate Drugs Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Imatinib Mesylate Drugs Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Imatinib Mesylate Drugs Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Imatinib Mesylate Drugs Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Imatinib Mesylate Drugs Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Imatinib Mesylate Drugs Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Imatinib Mesylate Drugs Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Imatinib Mesylate Drugs Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Imatinib Mesylate Drugs Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Imatinib Mesylate Drugs Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Imatinib Mesylate Drugs Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Imatinib Mesylate Drugs Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Imatinib Mesylate Drugs Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Imatinib Mesylate Drugs Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Imatinib Mesylate Drugs Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Imatinib Mesylate Drugs Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Imatinib Mesylate Drugs Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Imatinib Mesylate Drugs Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Imatinib Mesylate Drugs Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Imatinib Mesylate Drugs Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Imatinib Mesylate Drugs Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Imatinib Mesylate Drugs Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Imatinib Mesylate Drugs Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Imatinib Mesylate Drugs Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Imatinib Mesylate Drugs Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Imatinib Mesylate Drugs Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Imatinib Mesylate Drugs Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Imatinib Mesylate Drugs Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Imatinib Mesylate Drugs Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Imatinib Mesylate Drugs Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Imatinib Mesylate Drugs Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Imatinib Mesylate Drugs Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Imatinib Mesylate Drugs Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Imatinib Mesylate Drugs Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Imatinib Mesylate Drugs Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Imatinib Mesylate Drugs Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Imatinib Mesylate Drugs Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Imatinib Mesylate Drugs Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Imatinib Mesylate Drugs Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Imatinib Mesylate Drugs Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Imatinib Mesylate Drugs Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Imatinib Mesylate Drugs Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Imatinib Mesylate Drugs Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Imatinib Mesylate Drugs Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Imatinib Mesylate Drugs Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Imatinib Mesylate Drugs Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Imatinib Mesylate Drugs Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Imatinib Mesylate Drugs Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Novartis
  2. 8.1.1 Novartis Company Information
  3. 8.1.2 Novartis Business Overview
  4. 8.1.3 Novartis Imatinib Mesylate Drugs Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Novartis Imatinib Mesylate Drugs Product Portfolio
  6. 8.1.5 Novartis Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Imatinib Mesylate Drugs Value Chain Analysis
  2. 9.1.1 Imatinib Mesylate Drugs Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Imatinib Mesylate Drugs Sales Mode & Process
  6. 9.2 Imatinib Mesylate Drugs Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Imatinib Mesylate Drugs Distributors
  9. 9.2.3 Imatinib Mesylate Drugs Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst